Announcement of Periodic Review: Moody's Ratings announces completion of a periodic review of ratings of Johnson& Johnson. Global Credit Research- 26 Mar 2026. New York, March 26, 2026-- Moody's Ratings has completed a periodic review of the ratings of Johnson& Johnson and other ratings that are associated with this issuer.
Moody's Ratings (Moody's) affirmed the ratings of Baxter International Inc. (Baxter) including the Baa3 senior unsecured ratings, (P)Baa3 senior unsecured shelf rating, and the Prime-3 commercial paper rating. At the same time, we revised the outlook to negative from stable. The revision in the ou...
Moody's Ratings (Moody's) assigned a Aa3 rating to the new senior unsecured notes issuance of Abbott Laboratories (Abbott). In addition, we assigned a (P)Aa3 senior unsecured shelf registration. Abbott's existing ratings remain unchanged, and the outlook remains unchanged at stable. Abbott will us...
A director at Abbott Laboratories bought 10,000 shares at 108.733USD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...
A director at Boston Scientific Corp sold after exercising options/sold 160,901 shares at 93.495USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's dir...
A director at Johnson & Johnson sold 100,000 shares at 221.229USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.